Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$23.54 USD

23.54
12,327,695

+1.04 (4.62%)

Updated Aug 7, 2025 04:00 PM ET

Pre-Market: $23.60 +0.06 (0.25%) 8:44 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.

Zacks Equity Research

Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Down

by Zacks Equity Research

We are encouraged by Zimmer Biomet's (ZBH) consistent effort in product renovation through research and development.

Zacks Equity Research

Cerner's (CERN) Q3 Earnings Match Estimates, Bookings Up Y/Y

by Zacks Equity Research

Cerner (CERN) gains from strong segmental revenues in the third quarter. Guidance for 2018 is impressive.

Zacks Equity Research

Omnicell (OMCL) Earnings & Revenues Beat Estimates in Q3

by Zacks Equity Research

Omnicell's (OMCL) third-quarter 2018 performance impresses with year-over-year growth in earnings and revenues.

Zacks Equity Research

ResMed (RMD) Q1 Earnings & Sales Beat on Overall Growth

by Zacks Equity Research

ResMed (RMD) sees solid contributions from domestic and international businesses in Q1.

Zacks Equity Research

Merit Medical (MMSI) Tops Q3 Earnings & Revenue Estimates

by Zacks Equity Research

Merit Medical (MMSI) gains from solid segmental performance in Q3. Also, the company reiterated its guidance for 2018.

Zacks Equity Research

Stryker (SYK) Beats Q3 Earnings, Misses Sales Estimates

by Zacks Equity Research

Stryker's (SYK) Q3 results benefit from solid segmental performance. Also, the company sustained strength in International sales.

Zacks Equity Research

Will Advance Medical Buyout Aid Teladoc (TDOC) Q3 Earnings?

by Zacks Equity Research

Teladoc (TDOC) is expected to chip in with a solid top-line contribution from its acquisition of Advance Medical in Q3.

Zacks Equity Research

Can CAG Growth Steadily Drive IDEXX (IDXX) in Q3 Earnings?

by Zacks Equity Research

IDEXX's (IDXX) efforts to enhance its commercial capabilities in the United States to maintain a recurring revenue rise at CAG Diagnostics are encouraging.

Zacks Equity Research

Will Product Revenues Drive Masimo's (MASI) Q3 Earnings?

by Zacks Equity Research

Masimo's (MASI) Product revenues likely to drive Q3; guidance for 2018 raised.

Zacks Equity Research

McKesson (MCK) Beats Q2 Earnings, Misses Revenue Estimates

by Zacks Equity Research

McKesson's (MCK) Q2 results benefit from solid performance in the Medical-Surgical Solutions segment.

Zacks Equity Research

What's in Store for Weight Watchers' (WTW) Q3 Earnings?

by Zacks Equity Research

Weight Watchers (WTW) likely to see soft segmental revenues in Q3; EPS guidance raised.

Zacks Equity Research

Align Technology (ALGN) Beats on Earnings and Revenues in Q3

by Zacks Equity Research

Align Technology (ALGN) gains on solid contributions from Clear Aligner as well as Scanner and Service segments in Q3.

Zacks Equity Research

Will Robust ICL Sales Aid STAAR Surgical (STAA) Q3 Earnings?

by Zacks Equity Research

STAAR Surgical (STAA) is expected to pitch in a solid top-line contribution with its Implantable Collamer Lens (ICL) consisting of the EVO Visian ICL product line.

Zacks Equity Research

Will Amedisys' (AMED) Q3 Earnings Reflect Overall Gain?

by Zacks Equity Research

Amedisys' (AMED) Q3 is anticipated to benefit from a strong uptick across all its three business lines consisting of Home Health, Hospice and Personal Care.

Zacks Equity Research

LabCorp (LH) Q3 Earnings Lag Estimates, Guidance Tweaked

by Zacks Equity Research

Within LabCorp (LH) Diagnostics business the disposition of certain businesses and the implementation of the Protecting Access to Medicare Act (PAMA) dented growth.

Zacks Equity Research

Thermo Fisher (TMO) Beats on Q3 Earnings, Ups '18 Guidance

by Zacks Equity Research

Thermo Fisher (TMO) raises its 2018 revenue view, banking on a solid third-quarter operational performance, partially offset by a less favorable foreign exchange.

Zacks Equity Research

Edwards Lifesciences (EW) Earnings Beat, Revenues Miss in Q3

by Zacks Equity Research

Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q3.

Zacks Equity Research

Baxter International (BAX) Q3 Earnings Preview: Here's What to Look Out For

by Zacks Equity Research

Baxter (BAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Illumina (ILMN) Beats Earnings and Revenue Estimates in Q3

by Zacks Equity Research

Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories and microarray business in Q3.

Zacks Equity Research

Boston Scientific (BSX) Beats on Q3 Earnings, Misses Revenues

by Zacks Equity Research

Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q3.

Zacks Equity Research

Varian (VAR) Misses Earnings, Beats Revenue Estimates in Q4

by Zacks Equity Research

Varian's (VAR) Q4 results benefit from strong growth in Oncology Systems. Also, solid guidance boosts investors' optimism.

Zacks Equity Research

Can Medication Delivery Unit Aid Baxter's (BAX) Q3 Earnings?

by Zacks Equity Research

Baxter (BAX) likely to gain from strong Medication Delivery revenues; guidance for 2018 raised.

Zacks Equity Research

Will Healthcare Arm Drive BioTelemetry's (BEAT) Q3 Earnings?

by Zacks Equity Research

Product launches, synergies from LifeWatch acquisition and favorable payor mix are expected to have worked in favor of BioTelemetry's (BEAT) Healthcare arm in Q3.

Zacks Equity Research

Quest Diagnostics (DGX) Q3 Earnings Meet, Guidance Tweaked

by Zacks Equity Research

Quest Diagnostics (DGX) gains on successful execution of its strategy of accelerating growth in Q3.

Zacks Equity Research

PetMed (PETS) Q2 Earnings Grow Y/Y, Reorder Sales Solid

by Zacks Equity Research

PetMed's (PETS) reorder sales growth solid in Q2. Increased online sales buoy optimism.